Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics has made significant strides in 2024 with its lead drug, ATH434, nearing the completion of a pivotal Phase 2 trial for Multiple System Atrophy (MSA). Promising preliminary results and ongoing research bolster its potential in treating neurodegenerative diseases, especially Parkinsonian disorders. As the company anticipates major data releases in 2025, it continues to engage with the scientific community to advance its development programs.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
